Latest Hotspot

FDA Approves Geron's RYTELO™ for Treating Anemia in Lower-Risk MDS

13 June 2024
4 min read

Geron Corporation a biopharmaceutical company at the commercial stage focused on transforming the lives of those affected by blood cancers, announced today that the U.S. Food and Drug Administration has granted approval for RYTELO™ (imetelstat). This medication is indicated for adult patients suffering from low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia, who require four or more units of red blood cells every eight weeks and have not responded to, have lost response to, or are unsuitable for treatment with erythropoiesis-stimulating agents.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, stated, "With RYTELO's approval and accessibility, we are optimistic that qualified patients with lower-risk MDS may gain significant clinical advantages. This includes the potential to be free from the need for red blood cell transfusions and the symptoms of anemia for more than 24 weeks."

Dr. Scarlett elaborated, "RYTELO's approval as the inaugural telomerase inhibitor showcases the strength of our scientific innovations and the dedication of our team to progress in blood cancer treatment. As we mark this significant achievement, I want to express my gratitude to the patients, their families, advocates, healthcare professionals, study coordinators, site staff, scientists, and both current and former Geron employees and collaborators who played a crucial role in this milestone and our evolution into a commercial entity."

Lower-risk myelodysplastic syndromes (LR-MDS) are types of blood cancers that often escalate, necessitating more rigorous management of core symptoms such as anemia and consequent fatigue. Patients with symptomatic LR-MDS frequently require regular red blood cell transfusions, a dependency associated with adverse short- and long-term clinical outcomes, potentially diminishing quality of life and lifespan.

There remains a considerable unmet necessity for many LR-MDS patients, especially those with prognostic factors indicating poor outcomes. For those who do not respond to erythropoiesis-stimulating agents (ESA), existing treatment options are limited to specific sub-groups, underscoring the need for therapies offering prolonged and consistent independence from red blood cell transfusions.

The FDA's authorization of RYTELO is founded on the IMerge Phase 3 clinical trial results, which were documented in The Lancet. The IMerge trial achieved its primary and key secondary endpoints, revealing that RYTELO significantly increased rates of red blood cell transfusion independence compared to a placebo, for a minimum of eight consecutive weeks and notably, 24 weeks. The durability of RBC-TI in the RYTELO group was evident, with median durations for 8-week and 24-week responders being approximately one year and 1.5 years, respectively.

RYTELO™ (imetelstat) received FDA approval as an oligonucleotide telomerase inhibitor for adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) and transfusion-dependent anemia, requiring four or more red blood cell units over eight weeks, who have either not responded to or lost response to, or are unsuitable for erythropoiesis-stimulating agents. It is intended to be administered as a two-hour intravenous infusion every four weeks.

As a pioneering treatment, RYTELO works by inhibiting telomerase enzyme activity. Telomeres are protective structures at the ends of chromosomes that naturally shorten with each cell division. In LR-MDS, abnormal bone marrow cells often produce telomerase, which reconstructs these telomeres, enabling unregulated cell division. Developed and solely owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of June 13, 2024, there are 3 investigational drugs for the TERC target, including 38 indications, 6 R&D institutions involved, with related clinical trials reaching 24, and as many as 1200 patents.

Imetelstat represents a novel approach to targeting TERC and inhibiting telomerase activity, which is often dysregulated in cancer and hematologic disorders. Its Fast Track and Orphan Drug designations further highlight the potential impact of this drug in addressing unmet medical needs and improving outcomes for patients with rare and challenging conditions.

图形用户界面, 文本, 应用程序

描述已自动生成

Annexon Announces Phase 3 Success of ANX005 for Guillain-Barré Syndrome
Latest Hotspot
4 min read
Annexon Announces Phase 3 Success of ANX005 for Guillain-Barré Syndrome
13 June 2024
Annexon Reports Preliminary Success in Phase 3 Trial of Novel C1q Inhibitor ANX005 for Guillain-Barré Syndrome.
Read →
Quell Therapeutics Advances CAR-Treg Therapy QEL-001 to Efficacy Phase in Liver Transplant Trial
Latest Hotspot
3 min read
Quell Therapeutics Advances CAR-Treg Therapy QEL-001 to Efficacy Phase in Liver Transplant Trial
13 June 2024
Quell Therapeutics progresses QEL-001, their innovative CAR-Treg cell therapy, to the efficacy phase of the LIBERATE Phase 1/2 trial in liver transplant recipients.
Read →
Virion Therapeutics Reports Promising Phase 1b Results for HBV Treatment at EASL Congress
Latest Hotspot
3 min read
Virion Therapeutics Reports Promising Phase 1b Results for HBV Treatment at EASL Congress
12 June 2024
Virion Therapeutics Announces Encouraging Phase 1b Immunogenicity Data of New HBV Treatment VRON-0200 at EASL Congress.
Read →
FDA Greenlights Phase II/III Trial of KPG-121 Coupled with Abiraterone for Initial Therapy in mCRPC
Latest Hotspot
3 min read
FDA Greenlights Phase II/III Trial of KPG-121 Coupled with Abiraterone for Initial Therapy in mCRPC
12 June 2024
Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.